[go: up one dir, main page]

AR054208A1 - Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios - Google Patents

Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios

Info

Publication number
AR054208A1
AR054208A1 AR20050103084A ARP050103084A AR054208A1 AR 054208 A1 AR054208 A1 AR 054208A1 AR 20050103084 A AR20050103084 A AR 20050103084A AR P050103084 A ARP050103084 A AR P050103084A AR 054208 A1 AR054208 A1 AR 054208A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
heterocycloalkyl
heteroaryl
aryl
alkyl
Prior art date
Application number
AR20050103084A
Other languages
English (en)
Inventor
Alain Braun
Gilles Courtemanche
Olivier Crespin
Eykmar Fett
Cecile Pascal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34947722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR054208A1 publication Critical patent/AR054208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a derivados de oxopiperidina de formula general (1), a un procedimiento para su preparacion, a medicamentos y composiciones farmacéuticas en base a ellos y a compuestos intermediarios de síntesis. Estos compuestos son de aplicacion en el tratamiento y prevencion de la obesidad, diabetes y disfunciones sexuales y el tratamiento de enfermedades cardiovasculares. Reivindicacion 1: Compuesto que responde a la formula (1): en la cual: n es igual a 1; Ra, Ra', Rb y Rb' son idénticos o diferentes entre sí, y representan un átomo de hidrogeno o un grupo alquilo o cicloalquilo, Rb y Rb' pueden formar juntos, con los átomos de carbono del ciclo al que están unidos, un puente carbonado que comprende de 4 a 5 eslabones; R1 representa un grupo alquilo o cicloalquilo; R2 representa un grupo heteroarilo; R3 representa 1 a 3 grupos, idénticos o diferentes entre sí, situados en posiciones cualesquiera del nucleo al cual están unidos, y elegidos, entre los átomos de halogeno y los grupos alquilos, cicloalquilos, -OR, -NRR', -CO-NRR', -NR-CO-R', -NR-CONRR', -NR-COOR', -NO2, -CN y -COOR; R5 representa un átomo de hidrogeno, un grupo alquilo, o cicloalquilo; R4 se elige entre los grupos de formulas (a), (b) y (c) que se presentan más adelante, eventualmente, substituidos por un grupo oxo, o mono- o polisubstituido por un grupo arilo o heteroarilo; en las cuales p = 0, 1, 2 o 3, m = 0, 1 o 2, y, o bien a) X representa un eslabon -N(R10) -, donde R10, se elige entre: ò un grupo (CH2)x-OR8, (CH2)x-COOR8, -(CH2)x-NR8R9, (CH2)x-CO-NR8R9 o -(CH2)x-NR8-COR9, -(CH2)x-COR8 en los cuales x = 1, 2, 3 o 4; ò un grupo cicloalquilo o heterocicloalquilo fusionado con un grupo arilo o heteroarilo; ò un grupo cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo, alquilheteroarilo, -CO-alquilo, -CO-cicloalquilo, -CO-heterocicloalquilo, -CO-arilo, -CO-heteroarilo, -CO-alquilarilo, -CO-alquilheteroarilo, -CS-alquilo, -CS-cicloalquilo, -CS- heterocicloalquilo, -CS-arilo, -CS-heteroarilo, -CS-alquilarilo, -CS-alquilheteroarilo, -CS-NR8R9, C(=NH)-NR8R9, -SO2-alquilo-, -SO2-cicloalquilo, -SO2-heterocicloalquilo, -SO2-arilo, -SO2-heteroarilo, -SO2-alquilarilo, -SO2-alquilheteroarilo o -SO2- NR8R9, los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos, heteroarilos están eventualmente substituidos por 1 o varios grupos elegidos entre los átomos de halogeno y los grupos R, R', OR, NRR', -CO-NRR', -NRCOR', NRCONRR', -NO2, CN, - COOR, OCOR, COR,, OCONRR', NRCOOR'; los grupos cicloalquilos, heterocicloalquilos, están eventualmente fusionados con un grupo arilo o heteroarilo; o bien R10 forma con el átomo de nitrogeno al cual está unido y un átomo de carbono situado en una posicion cualquiera de la estructura cíclica de la formula (a), pero no adyacente a dicho átomo de nitrogeno, un puente que comprende de 3 a 5 eslabones, R8 y R9 se eligen, independientemente entre si, entre un átomo de hidrogeno y los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos, heteroarilos, alquilarilos, alquilheteroarilos, -CO-alquilos, -CO-cicloalquilos, -CO-heterocicloalquilos, -CO-arilos, -CO-heteroarilos, -CO-alquilarilos, -CO-alquilheteroarilos, -SO2-alquilos, - SO2-cicloalquilos, -SO2-heterocicloalquilos, -SO2-arilos, -SO2-heteroarilos, -SO2-alquilarilos, -SO2-alquilheteroarilos, -C(=NH)-NRR', -COOR, -CO-NRR', -CS-NRR' y -(CH2)x-OR, donde x = 0, 1, 2, 3 o 4, los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos y heteroarilos están substituidos, eventualmente, por uno o varios grupos elegidos entre los átomos de halogeno y los grupos R, R', OR, NRR', -CO-NRR', -NRCOR', NRCONRR', -NO2, CN, -COOR, OCOR, COR, OCONRR', NRCOOR'; o bien R8 y R9 forman juntos un cicloalquilo o un heterocicloalquilo; R y R' representan, independientemente entre si, un átomo de hidrogeno o un grupo alquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo o alquilheteroarilo, o pueden formar juntos un cicloalquilo o un heterocicloalquilo; o bien, b) X representa un eslabon -C(R6)(R7)-, donde R6 se elige entre: ò un átomo de hidrogeno, un átomo de halogeno; ò un grupo (CH2)x-OR8, (CH2)x-COOR8, -(CH2)x-NR8R9, (CH2)x-CO-NR8R9 o -(CH2)x-NR8-COR9, -(CH2)x-COR8 en los cuales x = 1, 2, 3 o 4; ò un grupo alquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo, alquilheteroarilo, -CO-alquilo, -CO-cicloalquilo, -CO-heterocicloalquilo, -CO-arilo, -CO- heteroarilo, -CO-alquilarilo, -CO-alquilheteroarilo, -CS-alquilo, -CS-cicloalquilo, -CS-heterocicloalquilo, -CS-arilo, -CS-heteroarilo, -CS-alquilarilo, -CS-alquilheteroarilo, -CS-NR8R9, C(=NH)-NR8R9; ò un grupo cicloalquilo o heterocicloalquilo, fusionado o no, situado en posicion espiro sobre el ciclo de formula (a) al cual está unido; un grupo cicloalquilo o heterocicloalquilo fusionado con un grupo arilo o heteroarilo; los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos o heteroarilos están substituidos, eventualmente, por uno o varios grupos elegidos entre los átomos de halogeno y los grupos R, R', OR, NRR', -CO-NRR', -NRCOR', NRCONRR', -NO2, CN, -COOR, OCOR, COR, OCONRR', NRCOOR'; los grupos cicloalquilos o heterocicloalquilos están eventualmente fusionados con un grupo arilo o heteroarilo; R7 se elige entre los átomos de halogeno y los grupos alquilos, cicloalquilos, arilos, heteroarilos, alquilarilos, alquilheteroarilos, -OR, -O-arilos, -O- heteroarilos, -O-alquilarilos, -O-alquilheteroarilos, -NRR', -CO-NRR', -NR-CO-R', -NR-CO-NRR', -NR-COOR', -NO2, -CN y -COOR; R8 y R9, se eligen, independientemente entre si, entre un átomo de hidrogeno y los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos, heteroarilos, alquilarilos, alquilheteroarilos, -CO-alquilos, -CO-cicloalquilos, -CO-heterocicloalquilos, -CO-arilos, -CO-heteroarilos, -CO-alquilarilos, -CO-alquilheteroarilos, -SO2-alquilos, -SO2-cicloalquilos, -SO2- heterocicloalquilos, -SO2-arilos, -SO2-heteroarilos, -SO2-alquilarilos, -SO2-alquilheteroarilos, -C(=NH)-NRR', -COOR, -CO-NRR', -CS NRR' y -(CH2)x-OR, donde x = 0, 1, 2, 3 o 4, los grupos alquilos, cicloalquilos, heterocicloalquilos, arilos y heteroarilos están substituidos, eventualmente, por uno o varios grupos elegidos entre los átomos de halogeno y los grupos R, R', OR, NRR', -CO-NRR', -NRCOR', NRCONRR', -NO2, CN, -COOR, OCOR, COR, OCONRR', NRCOOR'; o bien R8 y R9 forman juntos un cicloalquilo o un heterocicloalquilo; R y R' representan, independientemente entre si, un átomo de hidrogeno o un grupo alquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo o alquilheteroarilo, o pueden formar juntos un cicloalquilo o un heterocicloalquilo, en estado de base o de sal de adicion con un ácido, así como en estado de hidrato o de solvato.
AR20050103084A 2004-07-29 2005-07-26 Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios AR054208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408369A FR2873690B1 (fr) 2004-07-29 2004-07-29 Derives d'oxopiperidine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR054208A1 true AR054208A1 (es) 2007-06-13

Family

ID=34947722

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20050103084A AR054208A1 (es) 2004-07-29 2005-07-26 Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios

Country Status (25)

Country Link
US (1) US20070149562A1 (es)
EP (1) EP1773796B1 (es)
JP (1) JP4871866B2 (es)
KR (1) KR20070047802A (es)
CN (1) CN101010309A (es)
AR (1) AR054208A1 (es)
AT (1) ATE459608T1 (es)
AU (1) AU2005276353C1 (es)
BR (1) BRPI0512680A (es)
CA (1) CA2577177A1 (es)
CY (1) CY1110124T1 (es)
DE (1) DE602005019743D1 (es)
DK (1) DK1773796T3 (es)
ES (1) ES2341722T3 (es)
FR (1) FR2873690B1 (es)
IL (1) IL180770A (es)
MX (1) MX2007001139A (es)
PE (1) PE20060563A1 (es)
PL (1) PL1773796T3 (es)
PT (1) PT1773796E (es)
RU (1) RU2376298C2 (es)
SI (1) SI1773796T1 (es)
TW (1) TW200609217A (es)
UY (1) UY29036A1 (es)
WO (1) WO2006021655A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873691B1 (fr) * 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
EP2020405A1 (en) * 2007-07-30 2009-02-04 Santhera Pharmaceuticals (Schweiz) AG Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9744171B2 (en) 2012-03-06 2017-08-29 Vanderbilt University Positive allosteric modulators for melanocortin receptors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
WO2000074679A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
AU2001249296B2 (en) * 2000-03-23 2005-03-24 Merck Sharp & Dohme Corp. Substituted piperidines as melanocortin receptor agonists
AU2001288285B2 (en) * 2000-08-23 2005-09-29 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
JP2005511475A (ja) * 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
JP4336196B2 (ja) * 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
FR2873691B1 (fr) * 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP1773796A2 (fr) 2007-04-18
CY1110124T1 (el) 2015-01-14
WO2006021655A2 (fr) 2006-03-02
AU2005276353C1 (en) 2012-03-29
TW200609217A (en) 2006-03-16
FR2873690A1 (fr) 2006-02-03
IL180770A0 (en) 2007-06-03
ATE459608T1 (de) 2010-03-15
JP4871866B2 (ja) 2012-02-08
BRPI0512680A (pt) 2008-04-01
SI1773796T1 (sl) 2010-07-30
DK1773796T3 (da) 2010-06-21
PL1773796T3 (pl) 2010-08-31
RU2376298C2 (ru) 2009-12-20
WO2006021655A3 (fr) 2006-04-20
RU2007107374A (ru) 2008-09-10
AU2005276353A1 (en) 2006-03-02
EP1773796B1 (fr) 2010-03-03
UY29036A1 (es) 2006-02-24
IL180770A (en) 2011-10-31
PE20060563A1 (es) 2006-07-12
CA2577177A1 (fr) 2006-03-02
CN101010309A (zh) 2007-08-01
DE602005019743D1 (de) 2010-04-15
WO2006021655A8 (fr) 2007-05-24
FR2873690B1 (fr) 2006-10-13
KR20070047802A (ko) 2007-05-07
PT1773796E (pt) 2010-06-01
ES2341722T3 (es) 2010-06-25
AU2005276353B2 (en) 2011-12-01
JP2008508240A (ja) 2008-03-21
MX2007001139A (es) 2007-04-19
US20070149562A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
AR054208A1 (es) Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
CO6251201A2 (es) Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos
HRP20191469T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinase
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR045010A1 (es) Pirimidinas utiles como moduladores de canales ionicos cuya activacion es controlada por tension
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
AR070437A1 (es) Moduladores de beta - amiloide
AR038843A1 (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
AR054186A1 (es) Derivados de tetrahidroindazolona y tetrahidroindolona
AR067845A1 (es) Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica
AR067027A1 (es) Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
AR084430A1 (es) Di/tri-aza-espiro-alcanos c
ES2603931T3 (es) Compuestos de triazolo
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
AR076866A1 (es) Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo y heterociclo y el uso de las mismas
AR057959A1 (es) 5-pirazolpiperidinas-(sustituidas)
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR064136A1 (es) Derivados de espiro-piperidina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas con la accion antagonista del receptor v1a.
AR044906A1 (es) Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR040133A1 (es) Derivados de n-acilamino bencil eter

Legal Events

Date Code Title Description
FA Abandonment or withdrawal